RecruitingNCT04917887

Long-Term Follow-up Protocol

A Prospective, Observational, Long-Term Follow-Up (LTFU) Study to Evaluate the Long-Term Safety of the Krystal Biotech, Inc. Gene Therapy Backbone Products Using HSV-1 Backbone

Sponsor

Krystal Biotech, Inc.

Enrollment

50 participants

Start Date

May 25, 2021

Study Type

OBSERVATIONAL

Conditions

Recessive dystrophic epidermolysis bullosa Dystrophic Epidermolysis Bullosa Dominant Dystrophic Epidermolysis Bullosa

Summary

The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).

Eligibility

Min Age: 6 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with dominant dystrophic epidermolysis bullosa, dystrophic epidermolysis bullosa, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 6 Months and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.